Vizamyl FDA Approval History
Last updated by Judith Stewart, BPharm on June 22, 2020.
FDA Approved: Yes (First approved October 25, 2013)
Brand name: Vizamyl
Generic name: flutemetamol F 18
Dosage form: Injection
Company: GE Healthcare
Treatment for: Diagnosis and Investigation
Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders.
Development Timeline for Vizamyl
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.